Menu
We are a clinical stage company developing oral peptide and protein replacement therapies for significant unmet needs where an oral tablet holds the potential to transform the standard of care.
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
We have a collaboration agreement with OPKO to leverage our N-Tab™ technology for the development of an oral GLP-2 for Short Bowel Syndrome and GLP-1/glucagon for obesity.
Entera leverages a disruptive and proprietary oral delivery technology platform (N-Tab™) that is designed to stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Our pipeline includes five differentiated, first-in-class oral peptide programs expected to enter the clinic by 2025.
